Recent Posts

• HIVEC® provides comparable efficacy and safety to BCG for high-risk, non-muscle-invasive bladder cancer in HIVEC-HR RCT
• “If we could kill the tumour without radical surgery, boy would that be a boon for patients. And I think that’s where we are headed”
• Growing data points towards use of HIVEC® in high-risk and BCG-unresponsive patients following publication of HIVEC® bladder cancer RCT results
• “There’s a new vitality in bladder cancer. And it’s exciting to have come through 20 years of agony and start to see the fruits of all that labour”
• “We’re trying to find our patients’ urinary microbiota and see if it affects bladder disease”